your market intelligence analyst
Search Results
997 results
Your search is now limited to «Company News for Diabetes» expert search.
GlobeNewswire 08/19/2019 08:17
Transactions related to Novo Nordisk’s incentive programmes have resulted in a net transfer from Novo Nordisk of 7,962 B shares in the period from 9 August 2019 to 16 August 2019.
More from GlobeNewswire:
PR Newswire 08/13/2019 06:45
Lilly plans to share results on the remaining key secondary endpoint of proportion of patients achieving PASI 100 at 24 weeks in 2020.
More from PR Newswire:
PMLiVE 08/12/2019 07:47
These trials will investigate the use of Ozempic in different settings and fordifferent outcomes, as itcontinuesto gain on rival Trulicity from Eli Lilly.
More from PMLiVE:
Seeking Alpha 08/09/2019 16:14
Over the past 12 months, Novo Nordisk has increased our global diabetes market leadership by 0.8 percentage points to 28.3.
More from Seeking Alpha: 08/09/2019 09:34
Novo, an early mover together with Eli Lilly in the sector, has a 46% share of the global GLP-1 market.
More from
FiercePharma 08/09/2019 09:32
Novo Nordisk has suffered some well-documented insulin woes, but now the company has not just two, but three GLP-1 drugs stepping up to drive growth.
More from FiercePharma: (EU) 08/09/2019 01:00
Merck confirms full-year forecast Following a solid first half that was in line with expectations, Merck continues to forecast for the full year 2019 a moderate organic net sales increase of +3% to +5% over the previous year ...
More from (EU):
Medical Marketing & Media 08/08/2019 11:13
West shared her views on how pharma is using tech to make trials more efficient and connect with mobile-savvy patients, and how it’s facing up to data privacy challenges, in this edited transcript of her conversation with Marc Iskowitz for The MM&M Podcast. .
More from Medical Marketing & Media:
FierceBiotech 08/08/2019 09:52
Initial results from a study by Eli Lilly & Co., Apple and Evidation Health showed that a combination of consumer devices and mobile apps could potentially help spot people with mild cognitive impairment or mild dementia related to Alzheimer’s.
More from FierceBiotech:
BioPharma Dive 08/07/2019 17:29
Johnson will assume additional duties in M&A, while Wasserman is being promoted to vice president of corporate business development, overseeing transactions, technology and venture capital investments.
More from BioPharma Dive: 08/07/2019 05:57
Diabetes drug maker Novo Nordisk buys pill factory in North Carolina.
More from
ETHealthWorld (India) 08/06/2019 07:23
Diabetes drug maker Novo Nordisk buys pill factory in North Carolina, Health News, ET HealthWorld.
More from ETHealthWorld (India):
Motley Fool 08/05/2019 17:59
On Slide 14, as I mentioned earlier, our emerging markets business continues to be a core strength for Sanofi with sales up 10% in the second quarter.
More from Motley Fool:
BioPharma-Reporter 08/05/2019 12:30
Additionally, per the agreement, Novo Nordisk can license relevant intellectual property generated under the collaboration, although any future license would require mutual agreement on the commercial terms.
More from BioPharma-Reporter:
CNBC - Business 08/02/2019 16:35
Earlier this week, drugmaker Sanofi disclosed that it, Eli Lilly and Novo Nordisk had received subpoena from New York's AG.
More from CNBC - Business: 08/02/2019 07:13
Dr Ray Barlow, CEO at e-therapeutics, said: “We are very pleased that Novo Nordisk, a global leader in diabetes care and innovation, has chosen to extend our original agreement.
More from
pharmaphorum 08/02/2019 04:35
Novo Nordisk already has close links with Oxford, having set up a research facility there where its researchers are working alongside Oxford University academics to advance development of therapies for type 2 diabetes.
More from pharmaphorum:
ENDPOINTS 08/01/2019 10:28
Novo Nordisk is expanding their discovery pact with Oxford-based e-Therapeutics, adding the biotech’s new genomics tech in the hunt for new Type 2 diabetes drugs.
More from ENDPOINTS:
PharmaTimes 08/01/2019 07:26
E-theraputics has signed an extension to its existing research collaboration with Novo Nordisk in the type II diabetes space, which uses the company’s proprietary Network-Driven Drug Discovery (NDD) platform to discover potentially novel biological mechanisms and therapeutic approaches for a specific area of the condition.
More from PharmaTimes:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors


Diagnostics and Therapeutics


Drugs - Brand Names

Drugs - Generic



Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices



Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications